Skip to content Skip to menu

Green light flagged for Medicines Australia new Code of Conduct

Friday, 26 October 2012

Media Release

Medicines Australia welcomes the draft determination by the ACCC to grant authorisation for edition 17 of the Medicines Australia Code of Conduct.

“We are pleased that the ACCC acknowledges the new provisions in the Code which are major shift towards greater transparency, ensure appropriate interactions between companies and healthcare professionals and which provide greater clarity around the application of the Code,” Medicines Australia Chief Executive, Dr Brendan Shaw said.

“Our extensive consultation with consumer organisations, academics, peak doctor groups and other stakeholders have strengthened the Code for the better.

“We are particularly pleased that the ACCC acknowledges sectoral leadership by Medicines Australia in convening a multi-stakeholder transparency working group. This group will examine and report on appropriate ways to disclose payments to healthcare professionals at an individual level. Industry will play its part toward devising a constructive and effective solution for consumers on this issue,” he said.

The ACCC has requested further information from Medicines Australia on three matters: publication of reports in a searchable format, whether the complaints process could be made more accessible for individuals and potential inclusion of representatives of consumer and healthcare professionals on the Code Review Panel.

“Industry is keen to ensure its conduct and Code continues to reflect community expectations. We will consider the ACCC’s requests to work towards a smooth authorisation of the 17th edition of our Code.

The new Code of Conduct, which has been submitted to the ACCC for authorisation is available here (please follow link)


Contact Person:

Jamie Nicholson
Media Communications Manager
Phone: 0419 220 293


As COVID19 continues to spread, our thoughts go out to anyone who has been infected or impacted. We hope that you are taking the necessary precautions to keep safe and well, both at work and at home.

Medicines Australia continues to monitor the situation and take advice from the Department of Health and the World Health Organisation. We are focused on responding to the important short-term issues but are also ensuring we stay balanced and maintain a focus on the medium and long-term business for our industry along with the well-being of our people.

At Medicines Australia we have initiated the following to ensure we support containment measures to provide business continuity and the well-being of our staff.

  • All non-essential travel has been restricted or cancelled
  • All face-to-face meetings (with external stakeholders and members) have been changed to virtual meetings (where appropriate)
  • Staff have been provided with the latest official information on COVID-19 through a hot-link on the office intranet; this information is regularly monitored and updated
  • Flexible working arrangements are covered in our HR policy which will allow staff to work remotely, if or when required
  • Current IT infrastructure enables staff to work remotely and will be in use if any person needs to self-isolate
  • Visual reminders have been displayed around the office, providing information about best hygiene practices
  • Extra hand-sanitiser, tissues and cleaning products have been supplied to staff for their work spaces

Our latest information is located at